Abstract
Most of the newly developed drugs fails to achieve sufficient bioavailability in to brain due to low water solubility and low permeability. Drug delivery systems are one method for achieving entry of molecules to their desired site of action within the body. Dendrimers are the customizable nanopolymers with uniform and well-defined particle size and shape. Dendrimers are of eminent interest for biomedical applications because of their ability to cross cell membranes. This potential pharmaceutical delivery system crosses the blood brain barrier (BBB) and other important target points. The high level of control over the dendritic architecture (size, branching density, surface functionality) make dendrimers ideal carriers in the field of brain drug delivery of anticancer, antiinflammatory, and antimicrobial agents. Examples of dendrimers such as poly(amidoamine) (PAMAM), poly(propylene imine) (PPI) and polyether-copolyester (PEPE), Glyco, PEGylated, peptide and pH dendrimers are of outmost significance. These dendrimers carriy the drug molecules by physical interactions (encapsulation) or through chemical bonding (prodrug approach), while pH sensitive dendrimers are able to deliver drug molecules by alteration of ionic exchange in the brain microenvironment at the tumor site. Techniques employing dendrimers could be especially useful for drugs targeting to Alzheimer's and Prion's diseases. The present review should be of value to scientists who wish to work on the dendrimers for the delivery of molecules into the brain by systemic dosing.
Keywords: Dendrimer, blood-brain barrier, boron neutron capture therapy, brain targeting, PAMAM, VIVA GEL, L-DOPA, Caco-2, Transferrin, PEPE, PPI, Starburst, LRP1, BNCT, CT-MR
CNS & Neurological Disorders - Drug Targets
Title: Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
Volume: 10 Issue: 5
Author(s): Sarwar Beg, Abdus Samad, M. I. Alam and Iram Nazish
Affiliation:
Keywords: Dendrimer, blood-brain barrier, boron neutron capture therapy, brain targeting, PAMAM, VIVA GEL, L-DOPA, Caco-2, Transferrin, PEPE, PPI, Starburst, LRP1, BNCT, CT-MR
Abstract: Most of the newly developed drugs fails to achieve sufficient bioavailability in to brain due to low water solubility and low permeability. Drug delivery systems are one method for achieving entry of molecules to their desired site of action within the body. Dendrimers are the customizable nanopolymers with uniform and well-defined particle size and shape. Dendrimers are of eminent interest for biomedical applications because of their ability to cross cell membranes. This potential pharmaceutical delivery system crosses the blood brain barrier (BBB) and other important target points. The high level of control over the dendritic architecture (size, branching density, surface functionality) make dendrimers ideal carriers in the field of brain drug delivery of anticancer, antiinflammatory, and antimicrobial agents. Examples of dendrimers such as poly(amidoamine) (PAMAM), poly(propylene imine) (PPI) and polyether-copolyester (PEPE), Glyco, PEGylated, peptide and pH dendrimers are of outmost significance. These dendrimers carriy the drug molecules by physical interactions (encapsulation) or through chemical bonding (prodrug approach), while pH sensitive dendrimers are able to deliver drug molecules by alteration of ionic exchange in the brain microenvironment at the tumor site. Techniques employing dendrimers could be especially useful for drugs targeting to Alzheimer's and Prion's diseases. The present review should be of value to scientists who wish to work on the dendrimers for the delivery of molecules into the brain by systemic dosing.
Export Options
About this article
Cite this article as:
Beg Sarwar, Samad Abdus, I. Alam M. and Nazish Iram, Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796235023
DOI https://dx.doi.org/10.2174/187152711796235023 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Transcriptomics of Antipsychotic Drug Function: What have we Learned from Rodent Studies?
Current Psychopharmacology Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Apoptotic Signaling in Pancreatic Cancer – Therapeutic Application (Supplemental Data)
Current Cancer Therapy Reviews Advances in Molecular Therapeutic Approaches to Patients with Malignant Gliomas
Current Signal Transduction Therapy Preparation, Chemical and Electrical Characterizations of Lipid Nanoparticles Loaded with Dihydroxybenzophenone
Medicinal Chemistry Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design HSV-1 Viral Oncolysis and Molecular Imaging with PET
Current Cancer Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery